What is the drug tafamidis used for?
What is the drug tafamidis used for?
Tafamidis is used to treat cardiomyopathy (enlarged and thickened heart muscle) of wild type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) in adults to reduce death and hospitalization related to heart problems.
Is tafamidis FDA approved?
On May 3, the U.S. Food and Drug Administration approved Vyndaqel (tafamidis meglumine) and Vyndamax (tafamidis) capsules for the treatment of the heart disease (cardiomyopathy) caused by transthyretin mediated amyloidosis (ATTR-CM) in adults. These are the first FDA-approved treatments for ATTR-CM.
How long does it take for tafamidis to work?
Results were noticed in as little as 6 months, and remained consistent throughout the 30-month trial. The clinical studies of VYNDAQEL® (tafamidis meglumine) supported the approval of VYNDAMAX, which contains the same active ingredient.
What is the difference between tafamidis and tafamidis meglumine?
Tafamidis reduces the formation of monomers by attaching to the thyroxine-binding sites to stabilise the transthyretin molecule. Tafamidis meglumine is a salt formulation. An 80 mg dose of this formulation produces similar concentrations to the recommended daily dose of 61 mg tafamidis.
Is tafamidis an orphan drug?
About Tafamidis In 2012, tafamidis was granted orphan drug designation for transthyretin cardiomyopathy in both the EU and US.
Is tafamidis available in Australia?
Yes. This product will remain in the scheme for 5 years, starting on the date the product is first supplied in Australia. Approved therapeutic use: Vyndaqel is indicated for the treatment of adult patients with wild-type or hereditary transthyretin amyloid cardiomyopathy (ATTR-CM).
What is Tafamidis used to treat?
From Wikipedia, the free encyclopedia Tafamidis, sold under the brand names Vyndaqel and Vyndamax, is a medication used to delay disease progression in adults with certain forms of transthyretin amyloidosis (ATTR).
What is Tafamidis (Vyndaqel)?
Tafamidis (trade name Vyndaqel) is a drug used to delay loss of peripheral nerve function in adults with familial amyloid polyneuropathy (FAP), an orphan disease.
What is the AUC of Tafamidis?
The AUC of tafamidis is 47,864.31ng\\*h/mL. A 20mg oral dose of tafamidis is approximately 59% recovered in the feces, largely as unchanged drug. Approximately 22% of a 20mg oral dose is recovered in the urine, mostly as the glucuronide metabolite.
How is tafamidis metabolized and excreted?
The oral clearance of tafamidis is 0.263L/h. The apparent total clearance is 0.44L/h. Tafamidis is largely not subject to first pass or oxidative metabolism, being 90% unchanged after in in vitro experiments. Preclinical data suggest tafamidis is mainly metabolized through glucuronidation and excreted in bile.
